CD8A and neoplasm: Avenues to boost and engineer augmented CD8+ T cell responses in lung cancer are evolving quickly, and include novel adoptive cell strategies, advances in peptide, mRNA, viral, and cell-based vaccine approaches; and novel ways to engage critical tumor-surface contacts by activated cytolytic T cells.